Inovio Pharmaceuticals, Inc.
INO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $65 | $117 |
| % Growth | – | -100% | -44.1% | – |
| Cost of Goods Sold | $0 | $742 | $0 | $776 |
| Gross Profit | $0 | -$742 | $65 | -$659 |
| % Margin | – | – | 100% | -563.1% |
| R&D Expenses | $13,333 | $14,165 | $16,091 | $12,885 |
| G&A Expenses | $7,877 | $8,563,112 | $9,025 | $0 |
| SG&A Expenses | $7,877 | $8,563,112 | $9,025 | $6,825 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$8,554,934 | $0 | $0 |
| Operating Expenses | $21,210 | $22,343 | $25,116 | $19,711 |
| Operating Income | -$21,210 | -$23,085 | -$25,051 | -$20,370 |
| % Margin | – | – | -38,337% | -17,410.8% |
| Other Income/Exp. Net | -$24,286 | -$435 | $5,356 | $988 |
| Pre-Tax Income | -$45,497 | -$23,519 | -$19,695 | -$19,382 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$45,497 | -$23,519 | -$19,695 | -$19,382 |
| % Margin | – | – | -30,140.5% | -16,566.4% |
| EPS | -0.87 | -0.61 | -0.51 | -0.7 |
| % Growth | -42.6% | -19.6% | 27.1% | – |
| EPS Diluted | -0.87 | -0.61 | -725.11 | -0.7 |
| Weighted Avg Shares Out | 52,169 | 38,830 | 27,161 | 27,161 |
| Weighted Avg Shares Out Dil | 52,169 | 38,830 | 27,161 | 27,161 |
| Supplemental Information | – | – | – | – |
| Interest Income | $552,108 | $611 | $808 | $853 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $750 | $742 | $743 | $776 |
| EBITDA | -$44,747 | -$22,778 | -$18,951 | -$18,606 |
| % Margin | – | – | -29,002.7% | -15,903.3% |